$PPCB
Propanc Biopharma, Inc. Stock $ppcb

$ppcb Overview Financials Valuation SEC Filings Company Website

2023 Q3 Form 10-K Financial Statement

#000149315223034632 Filed on September 28, 2023

Income Statement

Concept	2023 Q3	2023 Q2	2023
Revenue		$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$401.0K	$203.9K	$1.529M
YoY Change	-14.96%	-58.46%	-11.88%
% of Gross Profit
Research & Development	$16.24K	$5.700K	$247.9K
YoY Change	-83.97%	-94.74%	-3.18%
% of Gross Profit
Depreciation & Amortization	$134.00	$320.00	$1.665K
YoY Change	-71.67%	-34.69%	-16.46%
% of Gross Profit
Operating Expenses	$417.2K	$209.6K	$1.777M
YoY Change	-27.17%	-65.02%	-10.76%
Operating Profit	-$417.2K		-$1.777M
YoY Change	-27.17%		-10.76%
Interest Expense	$178.2K	-$531.0K	$532.8K
YoY Change	9.51%	84.51%	-6.33%
% of Operating Profit
Other Income/Expense, Net	$66.35K		-$1.014M
YoY Change	-249.23%		40.37%
Pretax Income	-$350.9K	-$746.9K	-$2.790M
YoY Change	-43.16%	-17.43%	2.85%
Income Tax		$1.200K	-$129.8K
% Of Pretax Income
Net Earnings	-$350.9K	-$805.8K	-$2.661M
YoY Change	-43.16%	-10.94%	0.09%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.04		-$1.80
Diluted Earnings Per Share	-$0.04	-$0.22	-$1.80
COMMON SHARES
Basic Shares Outstanding	14.83M shares	3.288B shares	1.739M shares
Diluted Shares Outstanding	10.99M shares		1.739M shares

Balance Sheet

Concept	2023 Q3	2023 Q2	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$6.630K	$10.05K	$10.05K
YoY Change	-65.82%	146.93%	146.93%
Cash & Equivalents	$6.625K	$10.05K
Short-Term Investments
Other Short-Term Assets	$136.6K	$6.130K	$6.130K
YoY Change	765.88%	-28.89%	-28.89%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$145.8K	$19.04K	$19.04K
YoY Change	285.09%	26.67%	26.68%
LONG-TERM ASSETS
Property, Plant & Equipment	$160.00	$302.00	$39.29K
YoY Change	-88.87%	-85.07%	-39.13%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.930K	$2.000K	$2.000K
YoY Change	0.0%	-3.85%	-3.85%
Total Long-Term Assets	$34.57K	$41.29K	$41.29K
YoY Change	-38.7%	-38.02%	-38.02%
TOTAL ASSETS
Total Short-Term Assets	$145.8K	$19.04K	$19.04K
Total Long-Term Assets	$34.57K	$41.29K	$41.29K
Total Assets	$180.4K	$60.33K	$60.33K
YoY Change	91.37%	-26.11%	-26.11%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.081M	$966.7K	$1.011M
YoY Change	20.25%	2.51%	7.25%
Accrued Expenses	$1.215M	$1.189M	$1.189M
YoY Change	41.22%	31.72%	31.72%
Deferred Revenue
YoY Change
Short-Term Debt	$636.3K	$505.1K	$505.1K
YoY Change	-33.81%	-51.22%	-51.22%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$3.133M	$3.158M	$3.158M
YoY Change	11.01%	3.11%	3.11%
LONG-TERM LIABILITIES
Long-Term Debt	$23.37K	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$13.15K	$19.28K	$19.28K
YoY Change	-66.59%	-54.44%	-54.44%
Total Long-Term Liabilities	$36.52K	$19.28K	$19.28K
YoY Change	-7.23%	-54.45%	-54.44%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.133M	$3.158M	$3.158M
Total Long-Term Liabilities	$36.52K	$19.28K	$19.28K
Total Liabilities	$3.170M	$3.178M	$3.178M
YoY Change	10.76%	2.33%	2.33%
SHAREHOLDERS EQUITY
Retained Earnings	-$65.18M	-$64.68M
YoY Change	4.18%	5.08%
Common Stock	$14.83K	$6.031K
YoY Change	-97.81%	-97.26%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$46.48K	$46.48K
YoY Change	0.0%	0.0%
Treasury Stock Shares
Shareholders Equity	-$2.989M	-$3.117M	-$3.117M
YoY Change
Total Liabilities & Shareholders Equity	$180.4K	$60.33K	$60.33K
YoY Change	91.37%	-26.11%	-26.11%

Cashflow Statement

Concept	2023 Q3	2023 Q2	2023
OPERATING ACTIVITIES
Net Income	-$350.9K	-$805.8K	-$2.661M
YoY Change	-43.16%	-10.94%	0.09%
Depreciation, Depletion And Amortization	$134.00	$320.00	$1.665K
YoY Change	-71.67%	-34.69%	-16.46%
Cash From Operating Activities	-$333.5K	-$178.0K	-$1.105M
YoY Change	-34.53%	-56.7%	-23.05%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$24.71K
YoY Change			-75.11%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$350.3K	100.0K	$1.114M
YoY Change	-29.11%	-73.28%	-25.29%
NET CHANGE
Cash From Operating Activities	-$333.5K	-178.0K	-$1.105M
Cash From Investing Activities
Cash From Financing Activities	$350.3K	100.0K	$1.114M
Net Change In Cash	-$3.422K	-77.97K	$5.980K
YoY Change	-122.32%	112.45%	230.02%
FREE CASH FLOW
Cash From Operating Activities	-$333.5K	-$178.0K	-$1.105M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	PPCB	Deemed Dividend Upon Alternate Cashless Exercise Of Warrants DeemedDividendUponAlternateCashlessExerciseOfWarrants		usd
CY2022	PPCB	Stock Issued During Period Value Of Common Stock For Offering Cost StockIssuedDuringPeriodValueOfCommonStockForOfferingCost		usd
CY2022	PPCB	Stock Issued During Period Value Of Common Stock For Alternate Cashless Exercise Of Warrants StockIssuedDuringPeriodValueOfCommonStockForAlternateCashlessExerciseOfWarrants		usd
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001517681
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001517681
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--06-30
CY2022Q2	us-gaap	Loans Payable Current LoansPayableCurrent		usd
CY2023Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q2	PPCB	Subscription Receivable SubscriptionReceivable		usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax		usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax		usd
CY2022	PPCB	Gain From Settlement Of Accounts Payable GainFromSettlementOfAccountsPayable		usd
CY2023	PPCB	Retirement Of Series Preferred Stock RetirementOfSeriesPreferredStock		usd
CY2023	PPCB	Stock Issued During Period Value Of Common Stock For Alternate Cashless Exercise Of Warrants StockIssuedDuringPeriodValueOfCommonStockForAlternateCashlessExerciseOfWarrants		usd
CY2023	PPCB	Issuance Of Common Stock For Issuable Shares IssuanceOfCommonStockForIssuableShares		usd
CY2023	PPCB	Deemed Dividend Upon Alternate Cashless Exercise Of Warrants DeemedDividendUponAlternateCashlessExerciseOfWarrants		usd
CY2023	PPCB	Stock Issued During Period Value Reverse Stock Splits StockIssuedDuringPeriodValueReverseStockSplits		usd
CY2022	PPCB	Gain From Settlement Of Accounts Payable GainFromSettlementOfAccountsPayable		usd
CY2022	PPCB	Collection Of Subscription Receivable CollectionOfSubscriptionReceivable		usd
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2023	PPCB	Common Stock Issued For Offering Cost Applied Against Proceeds Received CommonStockIssuedForOfferingCostAppliedAgainstProceedsReceived		usd
CY2023	PPCB	Subscription Receivables SubscriptionReceivables		usd
CY2022	PPCB	Debt Discounts Related To Derivative Liability DebtDiscountsRelatedToDerivativeLiability		usd
CY2023	PPCB	Operating Lease Rightofuse Asset And Operating Lease Liability OperatingLeaseRightofuseAssetAndOperatingLeaseLiability		usd
CY2022	PPCB	Debt Discounts Related To Common Stock Issued With Note Payable DebtDiscountsRelatedToCommonStockIssuedWithNotePayable		usd
CY2022	PPCB	Non Cash Warrant Grant For Settlement Of Accounts Payable NonCashWarrantGrantForSettlementOfAccountsPayable		usd
CY2023	us-gaap	Stock Issued1 StockIssued1		usd
CY2023Q2	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2022Q2	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod		shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod		shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
CY2023	PPCB	Weighted Average Fair Value Of Options Granted During Period WeightedAverageFairValueOfOptionsGrantedDuringPeriod	P0Y
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted		shares
CY2022	PPCB	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Weighted Average Price Issued ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAveragePriceIssued
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures		shares
CY2022	PPCB	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Weighted Average Price Forfeited ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAveragePriceForfeited
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations		shares
CY2022	PPCB	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Weighted Average Price Expired ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAveragePriceExpired
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations		shares
CY2023	PPCB	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Weighted Average Price Expired ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAveragePriceExpired
CY2023Q2	PPCB	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Equity Instruments Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentsAggregateIntrinsicValueOutstanding		usd
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-06-30
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	000-54878
CY2023	dei	Entity Registrant Name EntityRegistrantName	PROPANC BIOPHARMA, INC.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	33-0662986
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	302
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	6 Butler Street
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Camberwell
CY2023	dei	Entity Address Country EntityAddressCountry	AU
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	3124
CY2023	dei	City Area Code CityAreaCode	61 03
CY2023	dei	Local Phone Number LocalPhoneNumber	9882 0780
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2022Q4	dei	Entity Public Float EntityPublicFloat	738451	usd
CY2023Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	14833210	shares
CY2023	dei	Auditor Firm AuditorFirmId	106
CY2023	dei	Auditor Name AuditorName	SALBERG & COMPANY, P.A
CY2023	dei	Auditor Location AuditorLocation	Boca Raton, Florida
CY2023Q2	us-gaap	Cash Cash	10047	usd
CY2022Q2	us-gaap	Cash Cash	4067	usd
CY2023Q2	us-gaap	Value Added Tax Receivable Current ValueAddedTaxReceivableCurrent	2867	usd
CY2022Q2	us-gaap	Value Added Tax Receivable Current ValueAddedTaxReceivableCurrent	2342	usd
CY2023Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	6125	usd
CY2022Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	8621	usd
CY2023Q2	us-gaap	Assets Current AssetsCurrent	19039	usd
CY2022Q2	us-gaap	Assets Current AssetsCurrent	15030	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	302	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2023	usd
CY2023Q2	us-gaap	Assets Assets	60328	usd
CY2022Q2	us-gaap	Assets Assets	81651	usd
CY2023Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	966718	usd
CY2022Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	943023	usd
CY2023Q2	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	579707	usd
CY2022Q2	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	466115	usd
CY2023Q2	us-gaap	Interest Payable Current InterestPayableCurrent	44709	usd
CY2022Q2	us-gaap	Interest Payable Current InterestPayableCurrent	57822	usd
CY2023Q2	us-gaap	Loans Payable Current LoansPayableCurrent	65280	usd
CY2023Q2	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	390539	usd
CY2022Q2	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	926438	usd
CY2023Q2	us-gaap	Derivative Liabilities DerivativeLiabilities	423209	usd
CY2022Q2	us-gaap	Derivative Liabilities DerivativeLiabilities	151262	usd
CY2023Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	587618	usd
CY2022Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	415799	usd
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	3158229	usd
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	3062981	usd
CY2023Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	19278	usd
CY2022Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	42319	usd
CY2023Q2	us-gaap	Liabilities Liabilities	3177507	usd
CY2022Q2	us-gaap	Liabilities Liabilities	3105300	usd
CY2023Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1500005	shares
CY2022Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1500005	shares
CY2023Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2022Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	10000000000	shares
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	10000000000	shares
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	6031250	shares
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	6031250	shares
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	220351	shares
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	220351	shares
CY2023Q2	us-gaap	Common Stock Value CommonStockValue	6031	usd
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	220	usd
CY2023Q2	PPCB	Common Stock Issuable Shares CommonStockIssuableShares	1621653	shares
CY2022Q2	PPCB	Common Stock Issuable Shares CommonStockIssuableShares	19597	shares
CY2023Q2	PPCB	Common Stock Issuable CommonStockIssuable	1621	usd
CY2022Q2	PPCB	Common Stock Issuable CommonStockIssuable	20	usd
CY2023Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	60311502	usd
CY2022Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	57364690	usd
CY2022Q2	PPCB	Subscription Receivable SubscriptionReceivable	-23758	usd
CY2023Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1294876	usd
CY2022Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1234549	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-64684732	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-61557893	usd
CY2023Q2	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	0.001	shares
CY2022Q2	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	0.001	shares
CY2023Q2	us-gaap	Treasury Stock Value TreasuryStockValue	46477	usd
CY2022Q2	us-gaap	Treasury Stock Value TreasuryStockValue	46477	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-3117179	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-3023649	usd
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	60328	usd
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	81651	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1499885	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1706452	usd
CY2023	us-gaap	Occupancy Net OccupancyNet	28841	usd
CY2022	us-gaap	Occupancy Net OccupancyNet	28366	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	247919	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	256052	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	1776645	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	1990870	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-1776645	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-1990870	usd
CY2023	us-gaap	Interest Expense InterestExpense	532821	usd
CY2022	us-gaap	Interest Expense InterestExpense	568798	usd
CY2023	us-gaap	Interest Income Other InterestIncomeOther	36	usd
CY2022	us-gaap	Interest Income Other InterestIncomeOther	5613	usd
CY2023	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-530330	usd
CY2022	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-99111	usd
CY2023	PPCB	Gain From Settlement Of Accounts Payable GainFromSettlementOfAccountsPayable	17499	usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	25969	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-17503	usd
CY2023	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	5885	usd
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-42395	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1013762	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-722194	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2790407	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2713064	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-129841	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-54977	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-2660566	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-2658087	usd
CY2023	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	466273	usd
CY2022	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	700340	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3126839	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3358427	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.80
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.80
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-49.23
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-49.23
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1738802	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1738802	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	68219	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	68219	shares
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3126839	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3358427	usd
CY2023	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	60327	usd
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	149345	usd
CY2023	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	60327	usd
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	149345	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3066512	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3209082	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	-3067573	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	99285	usd
CY2022	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	657125	usd
CY2022	PPCB	Stock Issued During Period Value Of Common Stock For Services And Accrued Expenses StockIssuedDuringPeriodValueOfCommonStockForServicesAndAccruedExpenses	763065	usd
CY2022	PPCB	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants	625001	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	335677	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	72513	usd
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	149345	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-2658087	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-3023649	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-3023649	usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	48469	usd
CY2023	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	1387723	usd
CY2023	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	138948	usd
CY2023	PPCB	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants	475000	usd
CY2023	PPCB	Issuance Of Common Stock In Connection With Note Payable Value IssuanceOfCommonStockInConnectionWithNotePayableValue	37500	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	411111	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	5551	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	2408	usd
CY2023	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	60327	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-2660566	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-2660566	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-3117179	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-3117179	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-2660566	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-2658087	usd
CY2023	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	138948	usd
CY2022	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	314626	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	2408	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	72513	usd
CY2023	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	5885	usd
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-42395	usd
CY2023	us-gaap	Depreciation Depreciation	1665	usd
CY2022	us-gaap	Depreciation Depreciation	1993	usd
CY2023	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	202952	usd
CY2022	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	47971	usd
CY2023	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	21266	usd
CY2022	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	3678	usd
CY2023	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-530330	usd
CY2022	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-99111	usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	25969	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-17503	usd
CY2023	PPCB	Gain From Settlement Of Accounts Payable GainFromSettlementOfAccountsPayable	17499	usd
CY2023	us-gaap	Other Noncash Expense OtherNoncashExpense	1838	usd
CY2022	us-gaap	Other Noncash Expense OtherNoncashExpense	2250	usd
CY2023	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-232674	usd
CY2022	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-452308	usd
CY2023	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	610	usd
CY2022	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	-1660	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-2182	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	8620	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	80975	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	18870	usd
CY2023	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	186912	usd
CY2022	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	29907	usd
CY2023	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	130511	usd
CY2022	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	65017	usd
CY2023	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	92474	usd
CY2022	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	63878	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-19857	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-3277	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1105251	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1436304	usd
CY2023	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	590250	usd
CY2022	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	766500	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	24711	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	99285	usd
CY2023	PPCB	Collection Of Subscription Receivable CollectionOfSubscriptionReceivable	23758	usd
CY2023	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	475000	usd
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	625001	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1113719	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1490786	usd
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-2488	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-52670	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	5980	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	1812	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	4067	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	2255	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	10047	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	4067	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	2883	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	2392	usd
CY2022	PPCB	Common Stock Issued For Offering Cost Applied Against Proceeds Received CommonStockIssuedForOfferingCostAppliedAgainstProceedsReceived	20000	usd
CY2022	PPCB	Subscription Receivables SubscriptionReceivables	23758	usd
CY2023	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	411111	usd
CY2022	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	335677	usd
CY2023	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	1016285	usd
CY2022	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	635303	usd
CY2023	PPCB	Debt Discounts Related To Derivative Liability DebtDiscountsRelatedToDerivativeLiability	93668	usd
CY2022	PPCB	Operating Lease Rightofuse Asset And Operating Lease Liability OperatingLeaseRightofuseAssetAndOperatingLeaseLiability	66201	usd
CY2023	PPCB	Debt Discounts Related To Common Stock Issued With Note Payable DebtDiscountsRelatedToCommonStockIssuedWithNotePayable	37500	usd
CY2023	PPCB	Non Cash Warrant Grant For Settlement Of Accounts Payable NonCashWarrantGrantForSettlementOfAccountsPayable	5551	usd
CY2022	us-gaap	Stock Issued1 StockIssued1	448440	usd
CY2023	PPCB	Deemed Dividend Upon Alternate Cashless Exercise Of Warrants1 DeemedDividendUponAlternateCashlessExerciseOfWarrants1	466273	usd
CY2022	PPCB	Deemed Dividend Upon Alternate Cashless Exercise Of Warrants1 DeemedDividendUponAlternateCashlessExerciseOfWarrants1	700340	usd
CY2023Q2	us-gaap	Stockholders Equity Note Stock Split StockholdersEquityNoteStockSplit	one-for-one thousand
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_845_eus-gaap--UseOfEstimates_zAoZeeJzCZmd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_865_zUSUJ73ZLZK">Use of Estimates</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. Significant estimates in the accompanying consolidated financial statements include the estimates of useful lives for depreciation, valuation of the operating lease liability and related right-of-use asset, valuation of derivatives, allowance for uncollectable receivables, valuation of equity based instruments issued for other than cash, the valuation allowance on deferred tax assets and foreign currency translation due to certain average exchange rates applied in lieu of spot rates on transaction dates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PROPANC BIOPHARMA, INC. AND SUBSIDIARY</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>June 30, 2023 and 2022</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q2	us-gaap	Foreign Currency Exchange Rate Translation1 ForeignCurrencyExchangeRateTranslation1	0.6664	pure
CY2022Q2	us-gaap	Foreign Currency Exchange Rate Translation1 ForeignCurrencyExchangeRateTranslation1	0.6915	pure
CY2021Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1085204	usd
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax	149345	usd
CY2022Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1234549	usd
CY2023	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax	60327	usd
CY2023Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1294876	usd
CY2023Q2	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	usd
CY2022Q2	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-129841	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-54977	usd
CY2023Q2	us-gaap	Value Added Tax Receivable Current ValueAddedTaxReceivableCurrent	2867	usd
CY2022Q2	us-gaap	Value Added Tax Receivable Current ValueAddedTaxReceivableCurrent	2342	usd
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	247919	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	256052	usd
CY2023	us-gaap	Income Tax Credits And Adjustments IncomeTaxCreditsAndAdjustments	-129841	usd
CY2022	us-gaap	Income Tax Credits And Adjustments IncomeTaxCreditsAndAdjustments	-54977	usd
CY2022Q2	us-gaap	Debt Instrument Unamortized Premium DebtInstrumentUnamortizedPremium	313127	usd
CY2023Q2	us-gaap	Long Term Debt LongTermDebt	390539	usd
CY2022Q2	us-gaap	Long Term Debt LongTermDebt	926438	usd
CY2023	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	202952	usd
CY2023	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p id="xdx_846_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_ztGGAhUCq0mh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_864_zJQn7Fw6GBDg">Reclassifications</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain prior period amounts have been reclassified to conform to the current period presentation. The reclassified amounts have no impact on the Company’s previously reported financial position or results of operations and relate to the presentation of accrued interest separately on the consolidated balance sheet, of which $<span id="xdx_90F_eus-gaap--InterestPayableCurrent_iI_c20220630_zH1XHML1pwS9" title="Interest Payable">57,822</span> was previously included in convertible notes, net of discounts and including premiums at June 30, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022Q2	us-gaap	Interest Payable Current InterestPayableCurrent	57822	usd
CY2023	us-gaap	Debt Instrument Convertible Terms Of Conversion Feature DebtInstrumentConvertibleTermsOfConversionFeature	Each holder of the notes and warrants has agreed to a 4.99% beneficial ownership conversion limitation (subject to certain noteholders’ abilities to increase such limitation to 9.99% upon 60 days’ notice to the Company), and certain notes may not be converted during the certain specified time period from the date of issuance
CY2023	us-gaap	Debt Instrument Convertible Threshold Percentage Of Stock Price Trigger DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger	0.0499	pure
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11476617244.12	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	127167.12	shares
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-2660566	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1105251	usd
CY2023Q2	PPCB	Working Capital Deficit WorkingCapitalDeficit	3139190	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-3117179	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-64684732	usd
CY2022	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	47971	usd
CY2023	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	411111	usd
CY2022	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	335677	usd
CY2023Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	25432	usd
CY2022Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	28623	usd
CY2023Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	25130	usd
CY2022Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	26600	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	302	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2023	usd
CY2023	us-gaap	Depreciation Depreciation	1665	usd
CY2022	us-gaap	Depreciation Depreciation	1993	usd
CY2023Q2	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	338362	usd
CY2022Q2	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	644980	usd
CY2023Q2	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	38994	usd
CY2022Q2	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	31669	usd
CY2023Q2	us-gaap	Debt Instrument Unamortized Premium DebtInstrumentUnamortizedPremium	91171	usd
CY2023Q2	PPCB	Deferred Tax Assets Warrant Derivative Liability DeferredTaxAssetsWarrantDerivativeLiability	7403	usd
CY2022Q2	PPCB	Deferred Tax Assets Warrant Derivative Liability DeferredTaxAssetsWarrantDerivativeLiability	7403	usd
CY2023Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	478273	usd
CY2022Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	363873	usd
CY2023Q2	PPCB	Deferred Tax Assets Prepaid Investor Services DeferredTaxAssetsPrepaidInvestorServices	575021	usd
CY2022Q2	PPCB	Deferred Tax Assets Prepaid Investor Services DeferredTaxAssetsPrepaidInvestorServices	427318	usd
CY2023Q2	PPCB	Deferred Tax Assets Non Cash Interest DeferredTaxAssetsNonCashInterest	758797	usd
CY2022Q2	PPCB	Deferred Tax Assets Non Cash Interest DeferredTaxAssetsNonCashInterest	709936	usd
CY2023Q2	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	321557	usd
CY2022Q2	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	293260	usd
CY2023Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent	4550	usd
CY2022Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent	4198	usd
CY2023Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Other DeferredTaxAssetsTaxDeferredExpenseOther	6553	usd
CY2022Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Other DeferredTaxAssetsTaxDeferredExpenseOther	6553	usd
CY2023Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	8910873	usd
CY2022Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	8759357	usd
CY2023Q2	PPCB	Deferred Tax Assets Foreign Exchange Loss DeferredTaxAssetsForeignExchangeLoss	-39379	usd
CY2022Q2	PPCB	Deferred Tax Assets Foreign Exchange Loss DeferredTaxAssetsForeignExchangeLoss	-39379	usd
CY2023Q2	PPCB	Deferred Tax Assets Revalue Of Derivative Liability DeferredTaxAssetsRevalueOfDerivativeLiability	572141	usd
CY2022Q2	PPCB	Deferred Tax Assets Revalue Of Derivative Liability DeferredTaxAssetsRevalueOfDerivativeLiability	460772	usd
CY2023Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	84028	usd
CY2022Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	84028	usd
CY2023Q2	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	11679818	usd
CY2022Q2	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	11077318	usd
CY2023Q2	us-gaap	Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts	202568	usd
CY2022Q2	us-gaap	Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts	170435	usd
CY2023Q2	PPCB	Deferred Tax Liabilities Gain On Extinguishment Of Debt DeferredTaxLiabilitiesGainOnExtinguishmentOfDebt	-47393	usd
CY2022Q2	PPCB	Deferred Tax Liabilities Gain On Extinguishment Of Debt DeferredTaxLiabilitiesGainOnExtinguishmentOfDebt	259470	usd
CY2023Q2	us-gaap	Deferred Tax Liabilities Deferred Expense Deferred Financing Costs DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts	369033	usd
CY2022Q2	us-gaap	Deferred Tax Liabilities Deferred Expense Deferred Financing Costs DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts	352981	usd
CY2023Q2	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	524208	usd
CY2022Q2	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	782886	usd
CY2023Q2	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	11155610	usd
CY2022Q2	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	10294432	usd
CY2023Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	11155610	usd
CY2022Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	10294432	usd
CY2023Q2	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	10400000	usd
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.26	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.25	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.25	pure
CY2023Q2	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2022Q2	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2023Q2	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2023	us-gaap	Unrecognized Tax Benefits Period Increase Decrease UnrecognizedTaxBenefitsPeriodIncreaseDecrease	0	usd
CY2022	us-gaap	Unrecognized Tax Benefits Period Increase Decrease UnrecognizedTaxBenefitsPeriodIncreaseDecrease	0	usd
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000	shares
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	3000000000	shares
CY2022Q2	PPCB	Number Of Preferred Stock Authorized Shares NumberOfPreferredStockAuthorizedShares	1500005	shares
CY2022Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	3001500005	shares
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	3000000000	shares
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	10000000000	shares
CY2022Q3	PPCB	Number Of Preferred Stock Authorized Shares NumberOfPreferredStockAuthorizedShares	1500005	shares
CY2022Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10001500005	shares
CY2020Q3	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	one-for-one thousand (1:1,000)
CY2023Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1500005	shares
CY2023Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2022Q2	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	99285	usd
CY2022Q2	PPCB	Subscription Receivable SubscriptionReceivable	-23758	usd
CY2022Q3	PPCB	Subscription Receivable SubscriptionReceivable	23758	usd
CY2022Q3	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	24711	usd
CY2023	PPCB	Subscription Receivable Value SubscriptionReceivableValue	23758	usd
CY2022Q2	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	1000	usd
CY2022Q2	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	8000	usd
CY2022Q2	us-gaap	Debt Instrument Fair Value DebtInstrumentFairValue	28572	usd
CY2022Q2	us-gaap	Convertible Debt Fair Value Disclosures ConvertibleDebtFairValueDisclosures	19572	usd
CY2022Q2	us-gaap	Derivative Fair Value Of Derivative Net DerivativeFairValueOfDerivativeNet	2069	usd
CY2022	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	335677	usd
CY2023Q2	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	168200	usd
CY2023Q2	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	16632	usd
CY2023Q2	us-gaap	Debt Instrument Fee Amount DebtInstrumentFeeAmount	1838	usd
CY2023Q2	us-gaap	Convertible Debt Fair Value Disclosures ConvertibleDebtFairValueDisclosures	369602	usd
CY2023Q2	us-gaap	Derivative Fair Value Of Derivative Net DerivativeFairValueOfDerivativeNet	352051	usd
CY2023	PPCB	Deemed Dividend DeemedDividend	466273	usd
CY2022	PPCB	Deemed Dividend DeemedDividend	700340	usd
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	0.059	shares
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	13730000
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	0.059	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4533000
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	0.059	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4533000
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	0.059	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	4533000
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y10M17D
CY2023	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	0	usd
CY2022	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	72513	usd
CY2023Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	0	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	0	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	0	shares
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	121	shares
CY2021Q2	PPCB	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Weighted Average Outstanding ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageOutstanding	179630
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	16	shares
CY2022	PPCB	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Weighted Average Price Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAveragePriceExercised	42860
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	105	shares
CY2022Q2	PPCB	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Weighted Average Outstanding ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageOutstanding	200270
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	3305	shares
CY2023	PPCB	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Weighted Average Price Issued ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAveragePriceIssued	10
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	13	shares
CY2023	PPCB	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Weighted Average Price Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAveragePriceExercised	52081
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures	1	shares
CY2023	PPCB	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Weighted Average Price Forfeited ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAveragePriceForfeited	2000000
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	3396	shares
CY2023Q2	PPCB	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Weighted Average Outstanding ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageOutstanding	5440
CY2023Q2	PPCB	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber	3379	shares
CY2023Q2	PPCB	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Weighted Average Exercisable ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisable	5467
CY2023	PPCB	Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instruments Outstanding Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerms	P2Y1M20D
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	3396	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	3396	shares
CY2023Q2	PPCB	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber	3379	shares
CY2023Q1	PPCB	Stock Issued During Period Shares Exercise Of Warrants StockIssuedDuringPeriodSharesExerciseOfWarrants	4	shares
CY2023	PPCB	Penalty Amount PenaltyAmount	30000	usd
CY2020Q4	PPCB	Royalties Percentage RoyaltiesPercentage	0.02	pure
CY2023Q2	PPCB	Unreimbursed Lab Fees UnreimbursedLabFees	18056	usd
CY2022Q2	PPCB	Unreimbursed Lab Fees UnreimbursedLabFees	14364	usd
CY2023	us-gaap	Royalty Expense RoyaltyExpense	0	usd
CY2022	us-gaap	Royalty Expense RoyaltyExpense	0	usd
CY2022Q2	PPCB	Incremental Borrowing Rate IncrementalBorrowingRate	0.08	pure
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	23990	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	19992	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	3199	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	40783	usd
CY2023Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y9M7D
CY2023	us-gaap	Payments For Rent PaymentsForRent	28841	usd
CY2022	us-gaap	Payments For Rent PaymentsForRent	28366	usd
CY2022	PPCB	Bonus Payable BonusPayable	144166	aud
CY2022	PPCB	Bonus Payable BonusPayable	99691	usd
CY2023	PPCB	Bonus Payable BonusPayable	73387	aud
CY2023	PPCB	Bonus Payable BonusPayable	48905	usd
CY2023Q2	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	96000	aud
CY2023Q2	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	64627	usd
CY2022Q2	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	82500	aud
CY2022Q2	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	56050	usd
CY2022	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	73500	usd
CY2023	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	79111	usd
CY2023Q2	us-gaap	Share Price SharePrice	0.135
CY2023Q2	us-gaap	Embedded Derivative Fair Value Of Embedded Derivative Liability EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability	423209	usd
CY2023Q2	us-gaap	Derivative Liabilities DerivativeLiabilities	423209	usd
CY2022Q2	us-gaap	Embedded Derivative Fair Value Of Embedded Derivative Liability EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability	151262	usd
CY2022Q2	us-gaap	Derivative Liabilities DerivativeLiabilities	151262	usd

Files In Submission

Name	View Source	Status
ppcb-20230630_cal.xml	Edgar Link	unprocessable
ppcb-20230630_pre.xml	Edgar Link	unprocessable
0001493152-23-034632-index-headers.html	Edgar Link	pending
0001493152-23-034632-index.html	Edgar Link	pending
0001493152-23-034632.txt	Edgar Link	pending
0001493152-23-034632-xbrl.zip	Edgar Link	pending
ex14-1.htm	Edgar Link	pending
ex21-1.htm	Edgar Link	pending
ex23-1.htm	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
fin_001.jpg	Edgar Link	pending
form10-k.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
ppcb-20230630.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
ppcb-20230630_def.xml	Edgar Link	unprocessable
ppcb-20230630_lab.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
form10-k_htm.xml	Edgar Link	completed
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PPCB
Propanc Biopharma, Inc. Stock $ppcb

2023 Q3 Form 10-K Financial Statement

#000149315223034632 Filed on September 28, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PPCB Propanc Biopharma, Inc. Stock $ppcb

2023 Q3 Form 10-K Financial Statement

#000149315223034632 Filed on September 28, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PPCB
Propanc Biopharma, Inc. Stock $ppcb